Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. · 2020
Read Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. by Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7418434.txt.
Introduction
Tang and co-authors review three forms of cell death and their links to cancer immunity. The three are ferroptosis, necroptosis, and pyroptosis. Each kills cells in a way that can wake up the immune system.
Immune checkpoint drugs help some patients, but most tumors resist them or resist cell death by apoptosis. The authors show how the three death paths can work with checkpoint drugs and boost attack by CD8+ T cells. Most proof so far comes from animal and cell studies. Human tissue data from public sources partly backs the link. The review maps a route to stronger combined cancer treatment.
Catalog record
| CREATOR | Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, Meng Q, Yu X, Shi S. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity By Rong Tang, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu, Si Shi Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-020-00946-7 ABSTRACT In recent years, cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has achieved considerable success in the clinic. However, ICIs are significantly limited by the fact that only one third of patients with most types of cancer respond to these agents. The induction of cell death mechanisms other than apoptosis has gradually emerged as a new cancer treatment strategy because most tumors harbor innate resistance to apoptosis. However, to date, the possibility of combining these two modalities has not been discussed systematically. Recently, a few studies revealed crosstalk between distinct cell death mechanisms and antitumor immunity. The induction of pyroptosis, ferroptosis, and necroptosis combined with ICIs showed synergistically enhanced antitumor activity, even in ICI-resistant tumors. Immunotherapy-activated CD8+ T cells are traditionally believed to induce tumor cell death via the following two main pathways: (i) perforin-granzyme and (ii) Fas-FasL. However, recent studies identified a new mechanism by which CD8+ T cells suppress tumor growth by inducing ferroptosis and pyroptosis, which provoked a review of the relationship between tumor cell death mechanisms and immune system activation. Hence, in this review, we summarize knowledge of the reciprocal interaction between antitumor immunity and distinct cell death mechanisms, particularly necroptosis, ferroptosis, and pyroptosis, which are the three potentially novel mechanisms of immunogenic cell death. Because most evidence is derived from studies using animal and cell models, we also reviewed related bioinformatics data available for human tissues in public databases, which partially confirmed the presence of interactions between tumor cell death and the activation of antitumor immunity. INTRODUCTION The mechanism by which the host immune system recognizes and kills tumor cells has not been well established. Whether dead tumor cells have immunogenic potential to elicit effective antitumor responses remains controversial because only nonself antigens are able to induce an immune response according to the “self/nonself” model that emerged in the 19th century [1]. Between the 1960s and 1980s, many studies reported that some treatment modalities, such as chemotherapy and radiotherapy, endow cancer cells with the ability to promote potent anticancer immunity [2, 3]. However, these findings were not widely acknowledged due to the lack of direct molecular evidence of tumor-associated antigen (TAA) involvement in antitumor immunity. In the 1990s and 2000s, several studies gradually elaborated TAA-directed antitumor immunity, ranging from how TAA-specific T cells survive negative selection in the thymus to how these T cells in the tumor microenvironment kill cancer cells [4, 5]. The “danger model” of immunity, which emerged in the 1990s, partially attributes the activation of the antitumor immune response to nonphysiological cell death and the subsequent release of specific molecules, which are referred to as damage-associated molecular patterns (DAMPs). These DAMPs bind receptors in various immune cells and trigger a series of immune responses, including the activation of innate and adaptive immune cells [6], opsonization or phagocytosis of dying cancer cells [7], and maturation of dendritic cells (DCs) [8]. Over a long period, the cell death mechanisms have been inaccurately classified in a dichotomized manner as follows: (i) apoptosis regulated by intrinsic pathways and extrinsic intervention and (ii) accidental necrosis. However, apoptosis is usually regarded as an immune-tolerogenic process. In 2014, two studies reported a potential mechanism by which apoptotic cells maintain immune silence [9, 10]; the authors postulated that apoptotic caspases play a key role in the immune-tolerogenic process despite the lack of a clear molecular mechanism. Five years later, Jiang et al. elucidated that caspase 3/6/7 activation causes the downregulation of cGAS, MAVS, and IRF3, which are essential proteins for the activation of innate immunity [11]. Similarly, necrosis-induced inflammation facilitates only tissue repair responses (which are largely immunoregulatory) but not effective anticancer immunity [1]. In this context, researchers introduced a novel concept, i.e., immunogenic cell death (ICD), which might be elicited by tumor vaccination, radiotherapy, and some types of chemotherapy [12]. For a long time, ICD was also referred to as immunogenic apoptosis (IA) because most types of ICD occur via apoptosis. In recent years, with the increasing awareness of cell death mechanisms, many nonapoptotic cell deaths have been defined. Necroptosis, pyroptosis, and ferroptosis are three widely studied nonapoptotic cell deaths, all of which harbor unique molecular characteristics. Functionally, their role under physiological conditions in mammals has not been well-defined. According to previous studies, mammalian necroptosis and pyroptosis primarily exist to counteract pathogen infections and trigger an inflammatory anti-microbial response through the release of DAMPs. Interestingly, several lines of evidence suggest that crosstalk exists between necroptosis and pyroptosis [13–15]. Activated necroptosis by the induction of receptor-interacting protein kinase 1 (RIPK3) facilitates NLRP3-caspase-1-mediated IL-1β secretion [13]. Subsequent experiments supported that necroptosis signaling could trigger the RIPK3-mixed lineage kinase-like (MLKL)-NLRP3-Caspase-1 axis using MLKL and inflammasome knockout models [14]. In contrast to the deletion of core apoptotic effectors, the genetic deletion of the key necroptotic machinery, i.e., RIPK3 and MLKL, has no important influence on animal development. Ferroptosis can be induced by physiological conditions, such as high extracellular glutamate. Evolutionally, the incorporation of polyunsaturated fatty acids (PUFAs) into cell membranes is significant for the development of complicated neuronal circuits, modulating membrane fluidity, and cell adaptation to environments with different temperatures [16]. The accumulation of PUFAs in membranes creates a vulnerability to lethal lipid peroxidation due to their ability to form stabilized radicals, and many reactive electrophiles targeting nucleophilic sites in vital proteins are generated in this process. Hence, one possible physiological function of ferroptosis is the elimination of cells with the excessive production of electrophilic intermediates [17]. Another thought-provoking question relates to the identification of the factors that switch the cell death pattern from apoptosis to nonapoptotic cell death. Existing evidence suggests that necroptosis is a backup cell death mechanism triggered when apoptosis is hindered, which is highlighted by caspase-8 inhibition of lethal necroptotic signaling [18]. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is a key factor that controls the sensitivity of cells to ferroptosis induction by regulating pro-ferroptotic lipid. Researchers unveiled ACSL4 as a target of caspase cleavage during bortezomib-induced apoptosis [19]. Therefore, it is biologically plausible that the inactivation of ACSL4 during apoptosis may inhibit the insertion of PUFAs into the membrane, thereby limiting the capability of cells to undergo ferroptosis. In contrast, cells that undergo ferroptosis because of cysteine deprivation have approximately 10% the normal level of intracellular GSH [20]. The reducing power of GSH may be required for the processing and activation of caspases 3 and 8 [21, 22]; hence, cells depleted of GSH could be unable to activate caspases. The main signal pathways of these nonapoptotic cell deaths are shown as Fig. 1. Many studies found that these cell death modalities were widely involved in cancer clearance. For example, genetically enhanced tumor-selective ferroptosis sensitivity obviously inhibited the formation and development of pancreatic cancer in genetically engineered mice [23]. This phenomenon was replicated through the administration of cyst(e)inase, which is a drug that depletes cysteine and cystine, suggesting a translatable means to inducing ferroptosis in pancreatic cancer [23]. Similarly, inducing necroptosis could dramatically increase the survival times of mice with orthotopic pancreatic cancer